36 related articles for article (PubMed ID: 22632102)
1. Modeling of corneal and retinal pharmacokinetics after periocular drug administration.
Amrite AC; Edelhauser HF; Kompella UB
Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):320-32. PubMed ID: 18172109
[TBL] [Abstract][Full Text] [Related]
2. Multistage vector delivery of sulindac and silymarin for prevention of colon cancer.
Scavo MP; Gentile E; Wolfram J; Gu J; Barone M; Evangelopoulos M; Martinez JO; Liu X; Celia C; Tasciotti E; Vilar E; Shen H
Colloids Surf B Biointerfaces; 2015 Dec; 136():694-703. PubMed ID: 26513752
[TBL] [Abstract][Full Text] [Related]
3. Preparation and Evaluation of Amino Acid Conjugates of Celecoxib as Prodrugs to Improve the Pharmacokinetic and Therapeutic Properties of Celecoxib.
Lee Y; Kim J; Kim W; Yoon IS; Jung Y
Pharmaceutics; 2020 Oct; 12(11):. PubMed ID: 33143357
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic switching of sulpiride, an anti-psychotic and prokinetic drug, to an anti-colitic drug using colon-specific drug delivery.
Kim D; Kim W; Jeong S; Kim D; Yoo JW; Jung Y
Drug Deliv Transl Res; 2019 Feb; 9(1):334-343. PubMed ID: 30426357
[TBL] [Abstract][Full Text] [Related]
5. Calcium Alginate and Calcium Alginate-Chitosan Beads Containing Celecoxib Solubilized in a Self-Emulsifying Phase.
Segale L; Giovannelli L; Mannina P; Pattarino F
Scientifica (Cairo); 2016; 2016():5062706. PubMed ID: 27127680
[TBL] [Abstract][Full Text] [Related]
6. Particle replication in nonwetting templates nanoparticles with tumor selective alkyl silyl ether docetaxel prodrug reduces toxicity.
Chu KS; Finniss MC; Schorzman AN; Kuijer JL; Luft JC; Bowerman CJ; Napier ME; Haroon ZA; Zamboni WC; DeSimone JM
Nano Lett; 2014 Mar; 14(3):1472-6. PubMed ID: 24552251
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological and dietary prevention for colorectal cancer.
Nolfo F; Rametta S; Marventano S; Grosso G; Mistretta A; Drago F; Gangi S; Basile F; Biondi A
BMC Surg; 2013; 13 Suppl 2(Suppl 2):S16. PubMed ID: 24267792
[TBL] [Abstract][Full Text] [Related]
8. General aspects of colorectal cancer.
Centelles JJ
ISRN Oncol; 2012; 2012():139268. PubMed ID: 23209942
[TBL] [Abstract][Full Text] [Related]
9. What should be considered on design of a colon-specific prodrug?
Jung Y; Kim YM
Expert Opin Drug Deliv; 2010 Feb; 7(2):245-58. PubMed ID: 20095945
[TBL] [Abstract][Full Text] [Related]
10. Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs.
Schönthal AH; Chen TC; Hofman FM; Louie SG; Petasis NA
Expert Opin Investig Drugs; 2008 Feb; 17(2):197-208. PubMed ID: 18230053
[TBL] [Abstract][Full Text] [Related]
11. Colon-specific delivery of celecoxib is a potential strategy to improve toxicological and pharmacological properties of the selective Cox-2 inhibitor: implication in treatment of familiar adenomatous polyposis.
Lee Y; Kim H; Kim W; Yoon JH; Jeong SH; Jung Y
J Drug Target; 2012 Jul; 20(6):524-34. PubMed ID: 22632102
[TBL] [Abstract][Full Text] [Related]
12. N-succinylaspart-1-yl celecoxib is a potential colon-specific prodrug of celecoxib with improved therapeutic properties.
Lee Y; Kim J; Kim H; Kang S; Yoon JH; Kim DD; Kim YM; Jung Y
J Pharm Sci; 2012 May; 101(5):1831-42. PubMed ID: 22334096
[TBL] [Abstract][Full Text] [Related]
13. Colonic delivery of celecoxib is a potential pharmaceutical strategy for repositioning the selective COX-2 inhibitor as an anti-colitic agent.
Kim W; Lee Y; Jeong S; Nam J; Lee S; Jung Y
Arch Pharm Res; 2015 Oct; 38(10):1830-8. PubMed ID: 25860026
[TBL] [Abstract][Full Text] [Related]
14. Celecoxib coupled to dextran via a glutamic acid linker yields a polymeric prodrug suitable for colonic delivery.
Lee Y; Kim J; Kim W; Nam J; Jeong S; Lee S; Yoo JW; Kim MS; Jung Y
Drug Des Devel Ther; 2015; 9():4105-13. PubMed ID: 26251576
[TBL] [Abstract][Full Text] [Related]
15. Colon-targeted celecoxib ameliorates TNBS-induced rat colitis: a potential pharmacologic mechanism and therapeutic advantages.
Lee Y; Kim W; Hong S; Park H; Yum S; Yoon JH; Jung Y
Eur J Pharmacol; 2014 Mar; 726():49-56. PubMed ID: 24462351
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
